![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
National Institute of Child Health and Human Development (NICHD) |
Information provided by: | National Institute of Child Health and Human Development (NICHD) |
ClinicalTrials.gov Identifier: | NCT00166608 |
Genotyping assays for polymorphisms in the interleukin 10(IL10)gene and the inducible nitric oxide synthase (iNOS) gene will be performed. Genotypes will be compared to the severity of toxicity following overdose.
Condition | Intervention |
Drug Toxicity |
Procedure: Blood sampling |
ChemIDplus related topics: | Acetaminophen |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | Measurement of Nitrotyrosine Adducts and Cytokines in Acetaminophen Overdose Patients |
Estimated Enrollment: | 200 |
Study Start Date: | December 2002 |
Study Completion Date: | September 2007 |
Primary Completion Date: | May 2007 (Final data collection date for primary outcome measure) |
It was recently reported that IL-10 is protective in APAP toxicity and it down-regulates iNOS production. In an ongoing PPRU Network study, plasma IL-10 levels were higher in patients that developed significant toxicity, as compared to those with minimal hepatic transaminase elevations. In these patients IL-10 elevation is likely a compensatory response to hepatic injury. To further examine the relationship of IL-10 and iNOS in the APAP overdose patients, we will examine genetic variability in the promotor regions of iNOS and IL-10 in patients with APAP overdose. Data from the literature indicate the polymorphisms in the promotor regions of iNOS and IL-10 influence the severity and expression of various diseases. In addition to genotyping for iNOS and IL10 promotor region polymorphisms, plasma levels of nitrotyrosine and IL-10 will be measured in overdose patients.
Blood samples will be obtained from study patients for the analysis of inflammatory cytokines and nitrotyrosine. Blood samples will be obtained at the time of blood sampling for the routine clinical management of the APAP overdose patient. Patients who are hospitalized will have study blood samples drawn at the time daily blood samples are obtained. The sampling will continue daily until the patient is discharged. In addition to blood sampling the following data will be collected: age, gender, race, circumstances of the ingestion, dose of the ingestion, treatment for the ingestion, concomitant therapy, medical history and cigarette use.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arkansas | |||||
Arkansas Children's Hospital | |||||
Little Rock, Arkansas, United States, 72202 | |||||
United States, Kentucky | |||||
Kosair Children's Hospital | |||||
Louisville, Kentucky, United States, 40202 | |||||
United States, Michigan | |||||
Children's Hospital of Michigan | |||||
Detroit, Michigan, United States, 48201 | |||||
United States, Missouri | |||||
Children's Mercy Hospital | |||||
Kansas City, Missouri, United States, 64108 | |||||
United States, North Carolina | |||||
University of North Carolina--Chapel Hill | |||||
Chapel Hill, North Carolina, United States, 27599 | |||||
United States, Ohio | |||||
Rainbow Babies & Children's Hospital | |||||
Cleveland, Ohio, United States, 44106 | |||||
United States, Texas | |||||
Texas Children's Hospital | |||||
Houston, Texas, United States, 77030 |
Principal Investigator: | Laura James, M.D. | Arkansas Children's Hospital Research Institute |
Pediatric Pharmacology Research Units Website 
![]()   |
Study ID Numbers: | PPRU-10369s |
First Received: | September 9, 2005 |
Last Updated: | February 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00166608 |
Health Authority: | United States: Federal Government |
|
|
|
|
![]() |